353 related articles for article (PubMed ID: 17062682)
21. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR; Schilsky RL; Hoke FJ; Williams D; Kindler HL; Sprague E; DeWitte M; Martino HK; Erickson J; Pandite L; Russo M; Lambert JM; Howard M; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4363-8. PubMed ID: 15240523
[TBL] [Abstract][Full Text] [Related]
22. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q.
Liebisch P; Eppinger S; Schöpflin C; Stehle G; Munzert G; Döhner H; Schmid M
Haematologica; 2005 Apr; 90(4):489-93. PubMed ID: 15820944
[TBL] [Abstract][Full Text] [Related]
23. A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.
Knox JJ; Siu LL; Chen E; Dimitroulakos J; Kamel-Reid S; Moore MJ; Chin S; Irish J; LaFramboise S; Oza AM
Eur J Cancer; 2005 Mar; 41(4):523-30. PubMed ID: 15737556
[TBL] [Abstract][Full Text] [Related]
24. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
25. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
Raymond E; Alexandre J; Faivre S; Vera K; Materman E; Boni J; Leister C; Korth-Bradley J; Hanauske A; Armand JP
J Clin Oncol; 2004 Jun; 22(12):2336-47. PubMed ID: 15136596
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck.
Bastholt L; Specht L; Jensen K; Brun E; Loft A; Petersen J; Kastberg H; Eriksen JG
Radiother Oncol; 2007 Oct; 85(1):24-8. PubMed ID: 17602769
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.
Harrington KJ; El-Hariry IA; Holford CS; Lusinchi A; Nutting CM; Rosine D; Tanay M; Deutsch E; Matthews J; D'Ambrosio C; Turner SJ; Pandeshwara JS; Bourhis J
J Clin Oncol; 2009 Mar; 27(7):1100-7. PubMed ID: 19171712
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
[TBL] [Abstract][Full Text] [Related]
31. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
[TBL] [Abstract][Full Text] [Related]
33. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
34. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
35. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Ribrag V; Dupuis J; Tilly H; Morschhauser F; Laine F; Houot R; Haioun C; Copie C; Varga A; Lambert J; Hatteville L; Ziti-Ljajic S; Caron A; Payrard S; Coiffier B
Clin Cancer Res; 2014 Jan; 20(1):213-20. PubMed ID: 24132920
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
Czito BG; Cohen DP; Kelsey CR; Lockhart AC; Bendell JC; Willett CG; Petros WP; D'Amico TA; Truax R; Hurwitz HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1066-72. PubMed ID: 17881149
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
[TBL] [Abstract][Full Text] [Related]
38. Phase I trial of radiochemotherapy with bendamustine in patients with recurrent squamous cell carcinoma of the head and neck.
Bottke D; Bathe K; Wiegel T; Hinkelbein W
Strahlenther Onkol; 2007 Mar; 183(3):128-32. PubMed ID: 17340070
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.
Wittgen BP; Kunst PW; van der Born K; van Wijk AW; Perkins W; Pilkiewicz FG; Perez-Soler R; Nicholson S; Peters GJ; Postmus PE
Clin Cancer Res; 2007 Apr; 13(8):2414-21. PubMed ID: 17438100
[TBL] [Abstract][Full Text] [Related]
40. First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN).
Jehn CF; Boulikas T; Kourvetaris A; Kofla G; Possinger K; Lüftner D
Anticancer Res; 2008; 28(6B):3961-4. PubMed ID: 19192656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
